Rapporten
Verifierade nyheter om finansiering, huvudkontor och ledarskap från världens mest innovativa företag
84 rapporter och fler
KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor
KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.
NeoGenomics Names Warren Stone Chief Executive Officer
NeoGenomics named President and COO Warren Stone CEO effective January 4, 2027, with Tony Zook becoming Executive Chair and the company emphasizing strategic continuity.
Teal Health Raises $22M Series A for At-Home HPV Cervical Cancer Screening
Teal Health raised a $22 million Series A led by .406 Ventures to expand partnerships and access to its at-home HPV cervical cancer screening.
Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints
Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.
Solstice Oncology Raises $225M Series A for Neoadjuvant Immuno-Oncology
Solstice Oncology launched with a $225 million Series A led by RA Capital Management to advance porustobart, a neoadjuvant immuno-oncology therapy.
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
Craif Closes Approximately $33M Series D for Urine-Based Cancer Test
Craif closed an approximately $33 million Series D, made up of about $30.7 million in equity and about $3.3 million in debt and co-led by Granite-Integral and Tauns Co., Ltd., bringing total capital raised to roughly $88 million.
CORE Biomedicine Raises $21M Series A for Precision Oncology Therapeutics
CORE Biomedicine closed a $21 million Series A co-led by UTokyo Innovation Platform and Elikon Venture, and its Japanese subsidiary received an AMED grant.
AdvanCell Raises $315M Series D for Targeted Alpha Therapies
AdvanCell closed an oversubscribed, upsized $315 million Series D led by Ally Bridge Group and co-led by Alpha Wave to advance ADVC001 toward Phase 3 and expand U.S. manufacturing.
Visar 9 rapporter • Sida 1 • Kategori: all
Ligga steget före marknaden
Få veckovisa insikter levererade till din inkorg. Ingen spam, bara intelligens.



